

14th Residential Course on Clinical Pharmacology of Antiretrovirals

Turin, 16-18 January 2019



Starhotels Majestic
corso Vittorio Emanuele II 54
Turin



View of the Mole Antonelliana, in Turin

14th Residential Course on Clinical Pharmacology of Antiretrovirals

Turin, 16-18 January 2019

COURSE DIRECTOR

Prof. G. Di Perri

Head of the Department of Infectious Diseases, University of Turin, Italy

SCIENTIFIC SECRETARIAT

S. Bonora, A. Calcagno

Department of Infectious Diseases, University of Turin, Italy

Phone: +39 011 4393980/4393867, Fax: +39 011 4393882

E-mail: stefano.bonora@unito.it - andrea.calcagno@unito.it

Organizing Secretariat and CME Provider

HealthData Consulting S.r.l.

Via Morghen, 27 Turin - Italy

Phone +39 011 0267950 - Fax +39 011 0267954

E-mail: segreteria@hdcons.it



COURSE RATIONALE

Rapid advances in HIV, HBV and HCV disease management require the ongoing attention of healthcare professionals involved in HIV, HBV and HCV medicine. This course will address the implications of new PK/PD information on strategies for clinical management. Information will be presented through a mix of didactic lectures and clinically relevant cases developed by an expert faculty of clinicians and researchers.

TARGET AUDIENCE AND CME CREDITS

Provider HealthData Consulting s.r.l. (n.546) has assigned **14 CME credits** according to Italian Health Ministry's criteria. CME credits will only be awarded to Italian participants who attend the entire course. These categories of health professionals are eligible for CME credit assignment: physicians, hospital pharmacists and biologists.

FACULTY

C. Alcantarini, Department of Infectious Diseases, University of Turin, Italy.

D. Back, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

S. Bhagani, Division of Infection and Immunity, University College London, UK.

M. Boffito, Chelsea and Westminster Hospital, London, UK.

L. Boglione, Department of Infectious Diseases, University of Turin, Italy.

S. Bonora, Department of Infectious Diseases, University of Turin, Italy.

M.R. Brunetto, Gastroenterology Unit, Hospital and University of Pisa, Italy.

R. Bruno, Institute of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

D. Burger, Department of Pharmacy, Radboud Institute for Health Sciences (RIHS), Radboud University Medical Centre, Nijmegen, The Netherlands.

A. Calcagno, Department of Infectious Diseases, University of Turin, Italy.

A. Castagna, Infectious Diseases, IRCCS San Raffaele - Vita-Salute San Raffaele University, Milan, Italy.

D. Cattaneo, Clinical Pharmacology Unit, "Luigi Sacco" Hospital, Milan, Italy.

A. Ciancio, Department of Gastroenterology, University of Turin, Italy.

P. Cinque, Infectious Diseases Unit, Fondazione Centro S. Raffaele Monte Tabor - H.S. Raffaele, Milan, Italy.

A. D'Avolio, Department of Infectious Diseases, University of Turin, Italy.

- G. Di Perri**, Department of Infectious Diseases, University of Turin, Italy.
- M. Ferrara**, Department of Infectious Diseases, University of Turin, Italy.
- C. V. Fletcher**, Departments of Pharmacy Practice and Division of Infectious Diseases, Department of Internal Medicine at the University of Nebraska Medical Center, USA.
- C. Flexner**, Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- M. Galli**, Department of Infectious Diseases, University of Milan, Italy.
- R. Garraffo**, Pharmacology Laboratory, CHU Pasteur, Nice France.
- V. Ghisetti**, Microbiology and Virology Laboratory, Amedeo di Savoia Hospital, Turin, Italy.
- S. Gianella Weibel**, Division of Infectious Diseases, University of California, San Diego, La Jolla, CA, USA.
- S. Khoo**, Department of Pharmacology & Therapeutics, University of Liverpool, UK.
- M. Lamorde**, Prevention Care and Treatment Department, Infectious Diseases Institute, Makerere University Kampala, Uganda.
- S. Letendre**, Departments of Medicine and Psychiatry, University of California San Diego, San Diego, CA, USA.
- L. Marinaro**, Department of Infectious Diseases, University of Turin, Italy.
- C. Marzolini**, Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland.
- C. Mussini**, Institute of Infectious Diseases, University of Modena, Italy.
- G. Nunnari**, Institute of Infectious Diseases, University of Messina, Italy.
- A. Owen**, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
- C.F. Perno**, Department of Health Sciences, Institute of Infectious and Tropical Diseases, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy - Department of Oncology and Haemato-Oncology, University of Milan, Milan, Italy.
- M. Puoti**, Infectious Diseases Unit, "Niguarda Ca' Granda" Hospital, Milan, Italy.
- D. Ripamonti**, Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
- M. Rizzetto**, Department of Gastroenterology, University of Turin, Italy.
- G.M. Saracco**, Department of Gastroenterology, University of Turin, Italy.
- M. Siccardi**, Department of Pharmacology & Therapeutics, University of Liverpool, UK.

Wednesday 16th JANUARY, AFTERNOON SESSION

13:30 CME registration and welcome lunch

14:30 Welcome and introduction (**G. Di Perri, S. Bonora, A. Calcagno**)

INTRODUCTION TO THE COURSE (Chair: **D. Back**)

15:00 Lecture: Why clinicians should know clinical pharmacology of antivirals (**G. Di Perri**)

SESSION I - MANAGEMENT OF POLYPHARMACY AND DDIs (Chair: **D. Back, R. Garaffo**)

15:30 Polypharmacy in HIV and HCV patients: not only drug interactions (**C. Marzolini**)

16:00 Before Liverpool site: how to evaluate a potential DDI (**M. Siccardi**)

16:30 Coffee break

17:00 Beyond Liverpool site: pharmacological support for the management of polypharmacy in HIV-positive patients (**D. Cattaneo**)

17:30 Beyond Liverpool site: how to evaluate the impact of a DDI in the clinical setting (**C. Alcantarini, S. Bonora**)

18:00 Closing Day 1 Remarks

Thursday 17th JANUARY, MORNING SESSION

SESSION II – TWO-DRUG REGIMEN FOR HIV INFECTION (Chair: **C. Mussini, A. Castagna**)

9:00 Trials evaluation (**D. Ripamonti**)

9:30 Two-drug regimen in HIV infection (**G. Di Perri**)

SESSION III - INSIGHTS ON CLINICAL PHARMACOLOGY OF ARVs (Chair: **S. Khoo, A. D'Avolio**)

10:00 Clinical pharmacology of new and upcoming ARV compounds (**M. Boffito**)

10:30 Case-based discussion on ARVs and DDIs in pregnancy (**D. Burger**)

11:00 Coffee break

11:30 Clinical pharmacology of TAF and Cobicistat: more data from the clinical ground (**S. Bonora**)

12:00 Case-based discussion: clinical pharmacology of INI + PI regimens (**M. Ferrara**)

12:30 The long-acting wave: perspectives and pipeline (**C. Flexner**)

13:00 Lunch

Thursday 17th JANUARY, AFTERNOON SESSION

SESSION IV - HCV: STILL OPEN ISSUES? (Chair: A. Ciancio, M. Galli)

- 14:00 HCV: from cure to eradication (**M. Puoti**)
- 14:30 HCV retreatment and management of HCV+ patients with ESLD/ESRD (**S. Bhagani**)
- 15:00 Which drug-drug interactions are still a concern in HCV treatment? (**L. Marinaro**)
- 15:30 Coffee break

SESSION V - HCV AFTER THE CURE, HBV TOWARDS A CURE (Chair: G.M. Saracco, V. Ghisetti)

- 16:00 Case-based discussion on extra-hepatic morbidities in HCV+ patients (**L. Boglione**)
- 16:30 Care of liver after HCV cure: from NAFLD to microbiome (**R. Bruno**)
- 17:00 Pipeline and new strategies for HBV treatment (**M. Brunetto**)
- 17:30 Perspectives on HDV treatment (**M. Rizzetto**)
- 18:00 Closing Day 2 Remarks

Friday 18th JANUARY, MORNING SESSION

SESSION VI - UPCOMING FUTURE (Chair: G. Nunnari, C.F. Perno)

- 9:00 Barriers to HIV cure (**S. Gianella Weibel**)
- 9:30 How clinical pharmacology could contribute to HIV cure? (**C. Fletcher**)
- 10:00 Are you ready for the nano world? (**A. Owen**)
- 10:30 The transition to new ARVs in low-income and middle-income countries (**M. Lamorde**)
- 11:00 Coffee break

SESSION VII - CNS (Chair P. Cinque)


- 11:30 Rethinking ARVs penetration and effectiveness in the CNS (**A. Calcagno**)
- 12:00 Rethinking ARVs and co-medications toxicity in the CNS (**S. Letendre**)
- 12:30 Closing Remarks (**G. Di Perri**)
- 13:30 CME test

COURSE LOCATION and HOTEL ACCOMMODATION

Starhotels Majestic

corso Vittorio Emanuele II 54, Torino

Tel +39 011 539153 - Fax +39 011 534963



REGISTRATION INCLUDES

- Admission to all course sessions
- Name tag
- Satchel
- Free onsite wireless
- Catering as per below

Please see what meals are included with your registration below:

DAY	MORNING BREAK	LUNCH	AFTERNOON BREAK	DINNER
Wednesday 16th January	<i>Not included</i>	Starhotels Majestic*	Starhotels Majestic	Starhotels Majestic
Thursday 17th January	Starhotels Majestic	Starhotels Majestic	Starhotels Majestic	Social Dinner
Friday 18th January	Starhotels Majestic	Starhotels Majestic**	<i>Not included</i>	<i>Not included</i>

* *Welcome lunch*

** *Light refreshment*

A Social Dinner will be offered to the Course's attendees.

Social Dinner is free of charge for participants, but is essential to confirm your presence.

In confirming your participation, let us know if you require a vegetarian meal, or if you have any food intolerance or allergies.





Carignano square with Vincenzo Gioberti statue in the old city center of Turin

Diamond Sponsor



Gold Sponsor



Silver Sponsor

abbvie



Organizing Secretariat and CME Provider



HealthData Consulting S.r.l.

Via Morghen, 27 Turin - Italy

Phone +39 011 0267950 - Fax +39 011 0267954

E-mail: segreteria@hdcons.it - Web: www.hdcons.it